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Abstract 
Heart failure (HF) and atrial fibrillation (AF) often coexist.
Subjects with permanent AF show the highest prevalence of HF.
Patients with incident AF have HF in a great number of cases and,
reciprocally, in patients with incident HF, an AF can be frequently
found. The simultaneous presence of the two conditions is associ-
ated with mortality rates higher than those observed in individuals
with only one or none of them. Interestingly, HF and AF could
synergistically promote in elderly patients the development of dis-
ability and dementia. Inflammatory mechanisms coupled with
changes of renin-angiotensin system, hormonal pathways and
neuro-mediators could simultaneously promote left atrium remod-
eling and sustain both HF and AF. Beta-blockers and digoxin seem
to have small therapeutic effect and limited influence on prognosis
in these very complex patients. Sinus rhythm restoration could
slow down the progression of disability in symptomatic subjects.
Recent evidence seem to suggest that upstream therapy coupled
with rehabilitation, and that AV node ablation associated with car-
diac resynchronization therapy could benefit subjects with HF and
AF. In conclusion, elderly patients simultaneously presenting
problems of cardiac function and arrhythmia are an important
challenge for geriatric medicine, and request important efforts to
improve their functional profile and prognosis.
The epidemiologic insight of the problem
Heart failure (HF) has a high prevalence in patients with atrial
fibrillation (AF), and, reciprocally, AF has a high prevalence in
patients with HF, as demonstrated by the specific age-related
results of some registries and population-based studies (Table 1).
The results of the EURObservational Research Programme on
Atrial Fibrillation (EORP-AF) Long-Term General Registry, which
enrolled subjects showing at least one arrhythmia episode in the
last 12 months, demonstrated that HF was the main reason for
admission in hospital or consultation in 10.4% of the whole popu-
lation. The proportion of patients with HF significantly differed
according to the type of AF, ranging from a minimum of 4.6%, for
paroxysmal AF, to 19.7%, for permanent AF (Figure 1) [1].
Most of the new cases of the arrhythmia develop in the 5 years
preceding and following the diagnosis of HF [2]. Indeed, the con-
cepts that AF begets HF and that HF begets AF are now widely
accepted. More in detail, in the Framingham Heart Study, among
the 1737 subjects with new onset AF (mean age: 75±12 years), a
diagnosis of HF was found in 37% of cases, while among the 1166
participants with incident HF (mean age: 79±11 years), the preva-
lence of AF was 62%. Accordingly, the risk to develop the arrhyth-
mia was more than two times higher in HF patients (HR=2.18;
95%CI=1.26-3.76), similar to the risk of incident HFpEF - HF
with preserved ejection fraction (EF) - (HR=2.34; 95%CI=1.48-
3.70), and higher than the risk of a new HFrEF - HF with reduced
EF - (HR=1.32; 95%CI=0.83-2.10) in AF subjects [3].
From epidemiology to pathophysiology
and vice versa
HF and AF have an interrelated pathophysiology. In fact, some
characteristics of HF, such as the increased filling pressures of left
ventricle, the higher amount of atrial fibrosis and remodeling, the
activation of neuro-hormonal pathways, and the triggering of pul-
monary veins automaticity can promote arrhythmia development.
Furthermore, in AF patients, left ventricular hypertrophy could be
also a marker of an abnormal ankle-brachial index, thus unreveal-
ing the presence of a significant arterial disease [4]. At the same
time, AF with rapid and irregular ventricular rates and the reduced
cardiac output can originate or worsen HF [5]. Epidemiological
data showed that, in elderly individuals, the persistent forms of the
arrhythmia can be associated with clinical and laboratory vari-
ables typical of a frail condition [6]. More recently, the pre-abla-
tion study of patients with paroxysmal AF evidenced values of
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myocardial energetics and left ventricular EF lower than those
observed in controls with stable sinus rhythm. These findings let us
hypothesize that even lone AF could be a marker of an occult car-
diomyopathy characterized by a subtle LV dysfunction [7]. Indeed,
the impact of AF on mortality is significant and additive to that of
HF, particularly at an advanced age. The Cardiovascular Health
Study Investigators demonstrated in 5673 subjects (mean age: 73
years) followed up for 13 years that mortality grew form 43%, in
those without AF and HF, to 66% (AF present) and 74% (HF pres-
ent), to reach 85% in individuals with both conditions. Basing on
these findings, the simultaneous presence of AF and HF was asso-
ciated with a three times higher mortality risk [8]. The
Framingham Heart Study results confirm these findings. During
the follow-up, which was stopped after a length of 8 years, both
HFrEF (HR=2.73; 95%CI=2.12-3.48) and HFpEF (HR=1.83;
95%CI=1.41-2.37) were associated with a significantly increased
mortality risk after a new episode of AF [3]. 
HF and AF are important in the elderly not only for their
adverse effects on survival. Incident dementia and disability are
associated with the arrhythmia [9]. In fact, the loss of atrial con-
traction and of atrio-ventricular synchrony, which characterize AF,
lead to the reduction of LV systolic function and cardiac output.
These modifications, through heart failure and stroke develop-
ment, can further originate alterations of physical performance,
functional status and neuro-cognitive profile [9]. Some evidence
supports these associations. First, in the Framingham Heart Study,
MRI scans showed that cardiac index reduction was related to a
parallel decrease of total brain volume [10]. Interestingly, later, the
AGES-Reykjavik Study found an intriguing inverse association
between the arrhythmia burden (i.e., sinus rhythm vs. paroxysmal
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Table 1. Specific age-oriented epidemiological associations between heart failure and atrial fibrillation in some registries and popula-
tion-based studies. 
Study                                                 Type of study                              Age-related result                     Reference
Acute Decompensated                                 In-hospital patients                               Prevalence of AF in >70 years             Maisel WH et al. Am J Cardiol 2003; 91
Heart Failure National                                                                                                      - LVEF >40%: 36%                                   (6 Suppl 1):2-8
Registry (ADHERE)                                                                                                          - LVEF <40%: 41%
Olmsted County Study                                  Population Study (1990-98)                  4-year incidence of AF in                      Tsang TS et al. Am J Cardiol 2004; 93:54-58
                                                                                                                                              >65 years old subjects with
                                                                                                                                              abnormal LV relaxation: 18%
National, Heart, Lung, and Blood               Discharged from hospital patients    ≥75 years subjects                                 McManus DD et al. JAMA 2013; 2: e005694
Institute - Sponsored Cardiovascular       and outpatients(2005-8)                       - Pre-existing AF: 65.7%
Research Network (CVRN)                                                                                           - Incident AF: 56.8%
EURObservational Research                      Registry of in-hospital and                   Prevalence of HF in AF patients         Fumagalli S et al. JACC: Clinical
Programme (EORP) -AF General              ambulatory patients with AF                ≥75 years: 55%                                        Electrophysiology 2015; 1:326-334
Pilot Registry                                                   (2012-13)
                                                                           Patients admitted for HF in UK          Prevalence of AF in                                Ziaei F et al. Int J Cardiol 2016: 214:410-1
                                                                           (2000-13)                                                  - 70-79 years: 36.8%
                                                                                                                                              - 80-89 years: 42.4%
                                                                                                                                              - 90-99 years: 40.5%
PREFER in AF                                                  Registry of AF patients (2012-13)       Prevalence of HF in >80 years            Hanon O et al. Int J Cardiol 2017; 232:98-104
                                                                                                                                              AF subjects: 30.3%
Swedish Heart Failure Registry                  Registry of HF patients (2000-12)      Highest observed AF prevalence        Sartipy U et al. JACC: Heart Failure 2017;
                                                                                                                                              in men >90 years with HFpEF: 77%   5:565-574 
Framingham Heart Study                             Population Study (1968-2014)             Lifetime risk of AF in 75 years old     Staerk L et al. BMJ 2018; 361:k1453
                                                                                                                                              subjects with elevated risk due to
                                                                                                                                              history of HF or MI
                                                                                                                                              (median follow-up: 8 years): 35.1%
AF, atrial fibrillation; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; LV, left ventricular; LVEF, LV ejection fraction; MI, myocardial infarction.
Figure 1. Heart failure (HF) as the main reason for admission in
hospital / consultation by type of atrial fibrillation (AF) in the
11096 patients enrolled in the EURObservational Research
Programme on Atrial Fibrillation (EORP-AF) Long-Term
General Registry. Adapted from: Table 2, Boriani et al. Europace
2018;20:747-57, doi:10.1093/europace/eux301, with permission
of the Oxford University Press on behalf of the European Society
of Cardiology. This material is not included under the open









AF vs. persistent or permanent AF) and total brain volume, always
estimated with MRI [11]. Lastly, in the AF Competence NETwork,
it was shown that also learning and memory skills progressively
reduced following the arrhythmic burden [12].
The problematic therapy of AF in HF patients
Therapy of HF and AF in elderly individuals presents some rel-
evant controversial issues. HF, especially if associated with AF,
acts as a prothrombotic cause. In particular, endothelial dysfunc-
tion, blood flow stasis, platelet activation, and the influence on the
coagulation cascade contribute to a higher than normal thrombo-
genic status [13]. Historical data showed that mean daily dose of
warfarin in AF patients should be reduced when HF is present.
Indeed, the results of the registrative studies of all the direct anti-
coagulants seem to be consistent with unaltered drug efficacy and
safety in subjects with and without HF [13].
Present Guidelines for the management of AF recommend the
use of beta-blockers and digoxin (Class I, Level of Evidence B) for
rate control in patients with HF, especially if with reduced EF [14].
However, the results of a meta-analysis found that beta-blocker
therapy was effective to reduce mortality and hospital admissions
in HF subjects with severe systolic dysfunction only if sinus
rhythm was present. The benefit of treatment was lost in patients
with AF [15]. Furthermore, even digoxin seems to show no bene-
fits on survival in AF elderly patients independently of the pres-
ence of HF [16]. At this regard, a recent sub-analysis of the ARIS-
TOTLE found that the effect of digoxin on mortality, independent-
ly of the presence of HF, was apparently neutral in AF patients if
treatment was started before the beginning of the study. However,
mortality was significantly higher in those individuals who need to
begin digoxin therapy during the conduction of the study
(HR=1.78; 95%CI=1.37-2.31) [17]. Furthermore, all-cause death
was directly related to digoxin concentration, with a greater level
of drug in those who died (0.62 vs 0.55 ng/mL, p<0.0001), and a
mortality risk 19% higher for each 0.5 ng/mL increase of drug con-
centration (HR=1.19; 95%CI=1.07-1.32) [17]. 
Sinus rhythm restoration could represent a useful tool to
improve cardiac function in elderly patients with persistent AF.
Indeed, in a recent experience, an effective electrical cardioversion
produced an improvement of longitudinal strain - a marker of left
ventricular performance assessed with speckle tracking analysis of
the echocardiogram - in 43 of the 48 (90%) subjects (age: 73 years)
evaluated few hours after the procedure. All segments of the car-
diac silhouette showed a better performance [18]. These positive
changes could explain the significant increase of physical perform-
ance, as evaluated with the Short Physical Performance Battery
(SPPB), in those who maintained the sinus rhythm at the follow-up
evaluation (mean length: 141 days). Interestingly, no difference
was present in those patients in whom AF relapsed (Δ SR vs AF =
+1.1±0.4, p=0.018) [19]. 
Psychological profile seems to exert a relevant role on progno-
sis of patients with HF and AF. In the AF-CHF trial (mean age: 66
years; left ventricular EF ≤35%), cardiovascular death was signif-
icantly higher in patients with elevated depressive symptoms as
assessed with the Beck Depression Inventory (score ≥14/63). In
detail, mild to moderate depression influenced prognosis
(OR=1.57; 95%CI=1.20-2.07) more than the choice of the rate-
rhythm-control strategy of the arrhythmia did [20]. Later, always
in the same trial, it was shown that the rhythm control strategy of
AF was associated to reduced cardiovascular mortality, when com-
pared to the rate-control one (OR=0.55; 95%CI=0.32-0.95), only
in those patients with high symptoms of anxiety, as evaluated with
the Anxiety Sensitivity Inventory [21].
In the AF population, atrial structure undergoes a continuous
remodeling process. Inflammation markers, angiotensin-II, aldos-
terone, endothelin-1 and the reactive oxygen species interact with
the traditional arrhythmia clinical risk-factors and with obesity to
change atrial myocardium and to promote AF relapse [22]. Basing
on these assumptions, the “routine vs. aggressive risk factor driven
upstream rhythm control for prevention of early AF in heart failure”
(RACE 3) trial compared a conventional approach to a new, “target-
ed therapy”, one to maintain sinus rhythm at the follow-up in
patients with HF and persistent AF. In the active arm, four therapies
were introduced: mineralocorticoid receptor antagonists, statins,
angiotensin converting enzyme inhibitors and/or receptor blockers,
and cardiac rehabilitation, including physical activity, dietary restric-
tions, and counselling. At the one-year follow-up, the 7-day Holter
monitoring demonstrated a higher proportion of patients with sinus
rhythm in the “targeted therapy” group (75 vs. 63%, p=0.042) [23]. 
The use of devices for cardiac resynchronization therapy
(CRT) proved to be an effective strategy to improve left ventricular
function independently of age [24]. Importantly, CRT is able to
produce, after only 6 months, an increase of physical performance,
as evaluated with SPPB, and a positive effect on neuro-cognition,
as evaluated with the Mini-Mental State Examination [25].
However, prognosis in CRT elderly patients is negatively influ-
enced by the presence of AF [24]. In the APAF-CRT trial, perma-
nent AF patients with HF (mean age >70 years; mean EF: 40%)
and narrow QRS were stratified to rate control strategy or to AV
node ablation and CRT therapy. After 16 months of follow-up, hos-
pitalizations for HF were significantly reduced in the group receiv-
ing the device, with an effect particularly evident in patients with
an EF ≤35%. The invasive strategy had an influence also on health-
related quality of life [26].
Conclusions
The interaction between AF and HF is complex. It can be
responsible of some important complications of the arrhythmia,
such as cognitive impairment, dementia and increased mortality.
Inferring directional relationships between AF, HF and the other
outcomes can be treacherous. However, the comprehension of the
mechanisms linking the arrhythmia to the several related clinical
conditions can greatly help to clarify patients’ prognosis [27].
Subjects with AF and HF need a multifaceted treatment strategy, as
patients with only HF often do [28]. In this scenario, beta-blockers
and digoxin seem to lose their relevance, while treatments
addressed to reduce atrial remodeling are becoming more impor-
tant. Rehabilitation programs and cardiac devices, two non-phar-
macological approaches, could significantly ameliorate the clinical
outcomes of patients with HF and AF. 
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